c-Myc Recombinant Rabbit Monoclonal Antibody [PS00-11] (HA721182)

UNIPROT #

P01106

PROTEIN NAME

c-Myc

SYNONYMS

AU016757 antibody;Avian myelocytomatosis viral oncogene homolog antibody;bHLHe39 antibody;c Myc antibody;Cellular myelocytomatosis oncogene antibody;Class E basic helix-loop-helix protein 39 antibody;MGC105490 antibody;MRTL antibody;Myc antibody;Myc protein antibody;Myc proto oncogene protein antibody;Myc proto-oncogene protein antibody;myc-related translation/localization regulatory factor antibody;MYC_HUMAN antibody;Myc2 antibody;myca antibody;MYCC antibody;Myelocytomatosis oncogene a antibody;Myelocytomatosis oncogene antibody;Niard antibody;Nird antibody;oncogene c-Myc antibody;Oncogene Myc antibody;OTTHUMP00000158589 antibody;OTTHUMP00000227763 antibody;Proto-oncogene c-Myc antibody;Protooncogene homologous to myelocytomatosis virus antibody;RNCMYC antibody;Transcription factor p64 antibody;Transcriptional regulator Myc-A antibody;V-Myc avian myelocytomatosis viral oncogene homolog antibody;v-myc myelocytomatosis viral oncogene homolog (avian) antibody;zc-myc antibody

SUBCELLULAR LOCATION

Nucleoplasm, nucleolus

FUNCTION

The proto-oncogene c-MYC is located on chromosome 8q24. It encodes a nuclear posphoprotein that acts as a growth promotor and transcription factor regulating a variety of cellular functions such as cell growth, differentiation and apoptosis. c-MYC is involved in the regulation of 10-15% of all human genes and is estimated to be involved in 20% of all human cancers. c-MYC is essential for early B-cell development in the bone marrow and the unregulated expression of c-MYC in germinal center B-cells increases the chances of oncogentic events for the development of B-cell lymphomas. Mutations, amplification, rearrangement, and translocation of the c-MyC gene have been associated with various hematopoietic tumors, leukemias, and lymphomas as well as a variety of carcinomas (e.g. thyroid, breast, endometrium) and gliomas. IHC for c-MYC overexpression (>40%) is used to screen and predict c-MYC rearrangements and distinguish diffuse large B-cell lymphoma (DLBCL) NOS from high grade B-cell lymphoma with c-MYC, BCL2 and/or BCL6 rearrangements or so-called “double or triple hit lymphomas” who tend to have aggressive behavior and poor outcome when treated with standard therapy. c-MYC protein is overexpressed in 90% of Burkitt lymphomas (BL) and caused by c-Myc gene translocation. tonsil and colon are recommended as positive and negative tissue controls for c-MYC. In the tonsil, protocols must be calibrated to provide a moderate to strong, distinct nuclear staining reaction in approximately 10% of lymphocytes scattered both in the interfollicular zones and in the reactive germinal centers of the tonsil. A weak, distinct nuclear staining reaction of mantle zone B-cells (app. 10-20%) should be seen. In colon, a weak to moderate nuclear staining reaction should be displayed in scattered epithelial cells in the basal crypts, whereas the luminal epithelial cells and smooth muscle cells of the tunica muscularis should be unstained.